Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals Inc (SNOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,022
  • Shares Outstanding, K 1,701
  • Annual Sales, $ 14,290 K
  • Annual Income, $ -3,460 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 1.45
  • Price/Sales 0.44
  • Price/Cash Flow N/A
  • Price/Book 1.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +169,422.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.37 +2.08%
on 11/14/25
4.25 -19.06%
on 10/16/25
-0.63 (-15.48%)
since 10/14/25
3-Month
3.37 +2.08%
on 11/14/25
5.60 -38.57%
on 08/18/25
-1.83 (-34.72%)
since 08/14/25
52-Week
1.75 +96.57%
on 04/07/25
6.92 -50.29%
on 08/14/25
+0.86 (+33.33%)
since 11/14/24

Most Recent Stories

More News
Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Revenues increased 14% for the quarter compared to prior year and 13% year-to-date

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...

SNOA : 3.44 (-2.82%)
Investors Chat: Instacart IPO

Instacart is profitable and growing. Is that enough to spark investor interest?

NFLX : 1,112.17 (-3.64%)
CPB : 31.29 (+0.19%)
LYV : 135.86 (-0.70%)
PEP : 145.85 (+0.57%)
SNOA : 3.44 (-2.82%)
UBER : 91.62 (-0.17%)
DASH : 206.96 (+6.02%)
AMZN : 234.69 (-1.22%)
WMT : 102.48 (-0.06%)
MCD : 307.03 (-0.18%)
DIS : 105.80 (-1.68%)
Augmented Reality Devices: Apple vs. Meta Platforms

Plus, how to plan for a healthier retirement.

TMUS : 216.08 (+0.70%)
META : 609.46 (-0.07%)
AAPL : 272.41 (-0.20%)
VZ : 41.06 (-0.12%)
T : 25.59 (-0.62%)
SNOA : 3.44 (-2.82%)
UBER : 91.62 (-0.17%)
COIN : 284.00 (+0.30%)
Sonoma Pharmaceuticals (NASDAQ: SNOA) and EMC Pharma Receives DAPA Registration for Microcyn Rx Products from U.S. Department of Defense

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a global healthcare company that is focused on the research, development and production of

SNOA : 3.44 (-2.82%)

Business Summary

Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus...

See More

Key Turning Points

3rd Resistance Point 3.69
2nd Resistance Point 3.61
1st Resistance Point 3.52
Last Price 3.44
1st Support Level 3.36
2nd Support Level 3.29
3rd Support Level 3.20

See More

52-Week High 6.92
Fibonacci 61.8% 4.94
Fibonacci 50% 4.33
Fibonacci 38.2% 3.72
Last Price 3.44
52-Week Low 1.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar